Dosage & Administration Biomarker testing Drug label People also ask

Phesgo

(hyaluronidase / pertuzumab / trastuzumab)

10 ML hyaluronidase-zzxf 2000 UNT/ML / pertuzumab-zzxf 60 MG/ML / trastuzumab-zzxf 60 MG/ML Injection [Phesgo]15 ML hyaluronidase-zzxf 2000 UNT/ML / pertuzumab-zzxf 80 MG/ML / trastuzumab-zzxf 40 MG/ML Injection [Phesgo]

BOXED WARNING

Dosage & administration

* For subcutaneous use in the thigh only.
* PHESGO has different dosage and administration instructions than intravenous pertuzumab and trastuzumab products.
* Do not administer intravenously.
* Perform HER2 testing using FDA-approved tests by laboratories with demonstrated proficiency.
* The initial dose of PHESGO is 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase administered subcutaneously over approximately 8 minutes, followed every 3 weeks by a dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase administered subcutaneously over approximately 5 minutes.
* Neoadjuvant: administer PHESGO by subcutaneous injection every 3 weeks and chemotherapy by intravenous infusion preoperatively for 3 to 6 cycles.
* Adjuvant: administer PHESGO by subcutaneous injection every 3 weeks and chemotherapy by intravenous infusion postoperatively for a total of 1 year (up to 18 cycles).
* MBC: administer PHESGO by subcutaneous injection and docetaxel by intravenous infusion every 3 weeks.

biomarker testing

Phesgo clinical details

Genetic testing requirements were obtained from the NCCN guidelines for each cancer type.

drug label

Phesgo prescribing information

Contact Medical Science Liaison Report Adverse Event

financial assistance

Phesgo financial assistance options

Co-pay savings program

commercial only

Phesgo Prescriber Service & Patient Consent Form

Phesgo Prescriber Service Form - Online Portal

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Foundation programs

under insured

no insurance

goverment insurance

65+

Phesgo Prescriber Service & Patient Consent Form

Phesgo Prescriber Service Form - Online Portal

Genentech Patient Foundation Application Form (1/2)

Genentech Patient Foundation Application Form (2/2) - Patient Consent Form

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

Phesgo FAQs

How is the dosage of Phesgo?Phesgo is available in 2 dosages, including 2,000-60-60 var units Injection 10 ml and 30,000-1,200-600 var units/15ml Injection 15 ml

What does Phesgo treat?Phesgo treats Breast Neoplasms, Extravasation of Diagnostic and Therapeutic Materials and Gastrointestinal Neoplasms

What is Phesgo made of?Phesgo contains hyaluronidase / pertuzumab / trastuzumab which is a HER2/neu Receptor Antagonist

How Is Phesgo Administered?Phesgo is administered as a Injectable

What Are The Phesgo Mechanism Of Action?Phesgo mechanism of action is HER2/Neu/cerbB2 Antagonists

FAQ Data Source